Cargando…
Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance
Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome characterized by a preserved ejection fraction but increased diastolic stiffness and abnormalities of filling. Although the prevalence of HFpEF is high and continues to rise, no effective therapies exist; however, the diabe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314384/ https://www.ncbi.nlm.nih.gov/pubmed/30567709 http://dx.doi.org/10.1085/jgp.201812259 |
_version_ | 1783384095057772544 |
---|---|
author | Slater, Rebecca E. Strom, Joshua G. Methawasin, Mei Liss, Martin Gotthardt, Michael Sweitzer, Nancy Granzier, Henk L. |
author_facet | Slater, Rebecca E. Strom, Joshua G. Methawasin, Mei Liss, Martin Gotthardt, Michael Sweitzer, Nancy Granzier, Henk L. |
author_sort | Slater, Rebecca E. |
collection | PubMed |
description | Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome characterized by a preserved ejection fraction but increased diastolic stiffness and abnormalities of filling. Although the prevalence of HFpEF is high and continues to rise, no effective therapies exist; however, the diabetic drug metformin has been associated with improved diastolic function in diabetic patients. Here we determine the therapeutic potential of metformin for improving diastolic function in a mouse model with HFpEF-like symptoms. We combine transverse aortic constriction (TAC) surgery with deoxycorticosterone acetate (DOCA) supplementation to obtain a mouse model with increased diastolic stiffness and exercise intolerance. Echocardiography and pressure–volume analysis reveal that providing metformin to TAC/DOCA mice improves diastolic function in the left ventricular (LV) chamber. Muscle mechanics show that metformin lowers passive stiffness of the LV wall muscle. Concomitant with this improvement in diastolic function, metformin-treated TAC/DOCA mice also demonstrate preserved exercise capacity. No metformin effects are seen in sham operated mice. Extraction experiments on skinned ventricular muscle strips show that the metformin-induced reduction of passive stiffness in TAC/DOCA mice is due to an increase in titin compliance. Using phospho-site-specific antibodies, we assay the phosphorylation of titin’s PEVK and N2B spring elements. Metformin-treated mice have unaltered PEVK phosphorylation but increased phosphorylation of PKA sites in the N2B element, a change which has previously been shown to lower titin’s stiffness. Consistent with this result, experiments with a mouse model deficient in the N2B element reveal that the beneficial effect of metformin on LV chamber and muscle stiffness requires the presence of the N2B element. We conclude that metformin offers therapeutic benefit during HFpEF by lowering titin-based passive stiffness. |
format | Online Article Text |
id | pubmed-6314384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63143842019-01-08 Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance Slater, Rebecca E. Strom, Joshua G. Methawasin, Mei Liss, Martin Gotthardt, Michael Sweitzer, Nancy Granzier, Henk L. J Gen Physiol Research Articles Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome characterized by a preserved ejection fraction but increased diastolic stiffness and abnormalities of filling. Although the prevalence of HFpEF is high and continues to rise, no effective therapies exist; however, the diabetic drug metformin has been associated with improved diastolic function in diabetic patients. Here we determine the therapeutic potential of metformin for improving diastolic function in a mouse model with HFpEF-like symptoms. We combine transverse aortic constriction (TAC) surgery with deoxycorticosterone acetate (DOCA) supplementation to obtain a mouse model with increased diastolic stiffness and exercise intolerance. Echocardiography and pressure–volume analysis reveal that providing metformin to TAC/DOCA mice improves diastolic function in the left ventricular (LV) chamber. Muscle mechanics show that metformin lowers passive stiffness of the LV wall muscle. Concomitant with this improvement in diastolic function, metformin-treated TAC/DOCA mice also demonstrate preserved exercise capacity. No metformin effects are seen in sham operated mice. Extraction experiments on skinned ventricular muscle strips show that the metformin-induced reduction of passive stiffness in TAC/DOCA mice is due to an increase in titin compliance. Using phospho-site-specific antibodies, we assay the phosphorylation of titin’s PEVK and N2B spring elements. Metformin-treated mice have unaltered PEVK phosphorylation but increased phosphorylation of PKA sites in the N2B element, a change which has previously been shown to lower titin’s stiffness. Consistent with this result, experiments with a mouse model deficient in the N2B element reveal that the beneficial effect of metformin on LV chamber and muscle stiffness requires the presence of the N2B element. We conclude that metformin offers therapeutic benefit during HFpEF by lowering titin-based passive stiffness. Rockefeller University Press 2019-01-07 /pmc/articles/PMC6314384/ /pubmed/30567709 http://dx.doi.org/10.1085/jgp.201812259 Text en © 2018 Slater et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Articles Slater, Rebecca E. Strom, Joshua G. Methawasin, Mei Liss, Martin Gotthardt, Michael Sweitzer, Nancy Granzier, Henk L. Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance |
title | Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance |
title_full | Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance |
title_fullStr | Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance |
title_full_unstemmed | Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance |
title_short | Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance |
title_sort | metformin improves diastolic function in an hfpef-like mouse model by increasing titin compliance |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314384/ https://www.ncbi.nlm.nih.gov/pubmed/30567709 http://dx.doi.org/10.1085/jgp.201812259 |
work_keys_str_mv | AT slaterrebeccae metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance AT stromjoshuag metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance AT methawasinmei metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance AT lissmartin metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance AT gotthardtmichael metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance AT sweitzernancy metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance AT granzierhenkl metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance |